Physiologically-Based Pharmacokinetic (PBPK) Modeling and Risk Assessment
暂无分享,去创建一个
[1] K. Bischoff,et al. Methotrexate pharmacokinetics. , 1971, Journal of pharmaceutical sciences.
[2] M E Andersen,et al. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. , 1984, Toxicology and applied pharmacology.
[3] M. Andersen,et al. Risk Assessment Extrapolations and Physiological Modeling , 1985, Toxicology and industrial health.
[4] F. A. Smith,et al. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.
[5] E J O'Flaherty,et al. Physiologically based models for bone-seeking elements. V. Lead absorption and disposition in childhood. , 1995, Toxicology and applied pharmacology.
[6] R. Coulombe,et al. Pharmacokinetics in Risk Assessment , 1996 .
[7] H J Clewell,et al. Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. , 2001, The Science of the total environment.
[8] Melvin E. Andersen,et al. Physiologically Based Pharmacokinetic Modeling : Science and Applications , 2005 .
[9] Melvin E Andersen,et al. New directions in incidence-dose modeling. , 2005, Trends in biotechnology.
[10] Harvey J Clewell,et al. Perchlorate and Radioiodide Kinetics Across Life Stages in the Human: Using PBPK Models to Predict Dosimetry and Thyroid Inhibition and Sensitive Subpopulations Based on Developmental Stage , 2007, Journal of toxicology and environmental health. Part A.